Fundraising Overview - The total amount raised from the initial public offering (IPO) in 2021 was RMB 62,532 million, with a net amount of RMB 55,925.88 million after deducting issuance costs of RMB 6,606.12 million [1][3] - As of June 30, 2025, the total amount of funds raised from the IPO was RMB 58,997.34 million, with various deductions leading to an actual investment amount of RMB 55,925.88 million [2][3] Fund Utilization - By June 30, 2025, the actual investment amount from the 2021 IPO was RMB 45,692.77 million, with specific allocations detailed in the report [8][9] - The company approved the use of surplus funds from the "Fermentation Method L-Alanine 5000 tons/year technical transformation and expansion project" and "Alternate annual production of 25,000 tons of L-Alanine and L-Valine project" to permanently supplement working capital [3][9] 2022 Fundraising - In 2022, the company raised RMB 699,999,981.40 through a targeted issuance of A-shares, with a net amount of RMB 68,380.91 million after deducting issuance costs of RMB 1,619.09 million [4][5] - As of June 30, 2025, the total investment from the 2022 fundraising was RMB 68,404.964 million, with specific allocations also detailed in the report [8][12] Fund Management - The company has established a fundraising management method to ensure the proper storage, approval, use, and supervision of the raised funds, adhering to relevant laws and regulations [5][9] - The company has signed tripartite and quadripartite supervision agreements with banks and securities firms to ensure compliance in the management of the raised funds [7][8] Project Updates - The company has not made any changes to the fundraising projects from both the 2021 IPO and the 2022 targeted issuance [10][11] - The company has approved the addition of products such as L-Valine and Inositol to the annual production of 50,000 tons of bio-based succinic acid and bio-based product raw material production base construction project [9][12]

Core Viewpoint - The article discusses an innovative method for chemically recycling mixed plastic waste into valuable chemical products, addressing the environmental challenges posed by plastic waste [2][3]. Group 1: Research Overview - The research, published in Nature, presents a strategy to convert eight common types of plastic waste into their original chemical components or other valuable compounds [3][10]. - The method focuses on identifying functional groups in mixed plastic waste to facilitate the separation and conversion of these materials into useful products [5][8]. Group 2: Methodology - The research team developed a solid-state NMR method to accurately identify the types of plastics present in the mixed waste, which is crucial for the subsequent processing steps [5][6]. - By using selective solvents, the team was able to dissolve and separate specific plastics from the mixed waste, followed by catalytic processes to convert these plastics into valuable products [6][7]. Group 3: Results and Innovations - The study successfully demonstrated the feasibility of the proposed strategy using a real-life plastic mixture, yielding various chemical substances such as benzoic acid, plasticizers, and hydrocarbons [7][8]. - The key innovation lies in the universal strategy designed to tackle the challenge of chemical recycling of mixed plastics, allowing for adjustments in chemical steps based on the initial identification of major components [8][10].

Core Points - The U.S. is pressuring China to lift restrictions on rare earth exports, revealing its anxiety over the trade situation [1][3] - China's rare earth exports fell by 34% in May, with significant impacts on military-grade materials [3][5] - The U.S. faces a long and costly process to rebuild its rare earth supply chain, estimated to take 8-10 years and require hundreds of billions of dollars [5] - The trade war is reshaping global supply chains, with China transitioning from a reactive stance to a rule-setting position [3][5] - The U.S. is experiencing a dual challenge of needing to constrain China while simultaneously relying on its resources [5][9] Group 1: U.S.-China Trade Negotiations - The U.S. delegation, including key economic officials, is demanding China restore rare earth exports to April levels [1] - There is a disconnect in the negotiations, with the U.S. pushing for concessions while China calls for the removal of recent export restrictions [5][9] - The U.S. has violated previous agreements, such as the Geneva consensus, which has weakened the economic relationship [7] Group 2: China's Strategic Position - China holds significant leverage in the rare earth market, controlling 92% of refining and 99% of heavy rare earth processing [3] - The country is also advancing in other strategic sectors like renewable materials and biotechnology, further enhancing its bargaining power [5][9] - China's customs data shows a sharp decline in graphite electrode exports to the U.S., critical for the American steel industry [7] Group 3: Economic Implications - A complete decoupling of U.S.-China technology could lead to a global GDP decline of $1.5 trillion, equivalent to the entire economy of Australia [7] - The ongoing trade tensions are detrimental to both nations, with the U.S. potentially facing greater losses if it continues its current approach [9]

Core Viewpoint - Synthetic biology is a multidisciplinary field that integrates biology, informatics, genomics, and chemistry to design and construct artificial biological systems, marking a significant leap from understanding life to designing it, often referred to as the third biotechnology revolution [7][11]. Summary by Sections Synthetic Biology Overview - Synthetic biology involves the engineering of biological systems to produce valuable products through modified chassis cells that express specific genes to obtain target products [7][9]. - The core principles of synthetic biology include standardization, decoupling, and modularization, which facilitate the design and construction of biological systems [8][9]. Market Growth and Trends - The global synthetic biology market is projected to grow at a CAGR of 24%, reaching approximately $18.885 billion by 2024 [16][19]. - The healthcare sector is expected to be the largest segment, with a market size of $5.022 billion by 2024, accounting for 26.6% of the overall market [19]. Technological Advancements - Advances in gene sequencing, editing, and synthesis technologies have significantly reduced costs and barriers to entry in synthetic biology, enabling rapid development and iteration of engineered organisms [39][40]. - The integration of AI and big data in molecular design is accelerating the development of synthetic biology applications [39]. Applications and Benefits - Synthetic biology can replace traditional chemical synthesis or natural extraction methods, improving production economics and environmental sustainability [29][33]. - The technology allows for the production of a wide range of products, including pharmaceuticals, chemicals, and biofuels, using renewable resources and reducing reliance on fossil fuels [35][36]. Investment and Policy Support - There has been a surge in investment in synthetic biology, with global financing reaching $18 billion in 2021, nearly doubling from previous years [44]. - Governments in the U.S. and China are prioritizing synthetic biology in their strategic plans, recognizing its potential for innovation and economic growth [42][43].